Effects of Nicorandil on Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats
Authors:
- Minoru HongoMHMinoru Hongo
- Eiichiro MawatariEMEiichiro Mawatari
- Akio SakaiASAkio Sakai
- Zonghai RuanZRZonghai Ruan
- Tomonobu KoizumiTKTomonobu Koizumi
- Fumiko TerasawaFTFumiko Terasawa
- Yoshikazu YazakiYYYoshikazu Yazaki
- Osamu KinoshitaOKOsamu Kinoshita
- Uichi IkedaUIUichi Ikeda
- Toshishige ShibamotoTSToshishige Shibamoto
- 1 October 2005
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 46 (4) , 452-458
Abstract
We investigated whether nicorandil might prevent and reverse monocrotaline (MCT)-induced pulmonary arterial hypertension. Rats were injected with 50 mg/kg of MCT subcutaneously and randomized to either 7.5 mg/kg/d of nicorandil in drinking water or placebo for 3 weeks. Animals that were treated with MCT and survived for 3 weeks were assigned to either nicorandil or placebo. Nicorandil markedly attenuated pulmonary arterial hypertension with severe structural remodeling of the pulmonary vessels. The survival rate at 3 weeks after treatment was significantly increased in the nicorandil group compared with the placebo group (73% versus 39%, P < 0.05). In the placebo group, endothelial nitric oxide synthase (eNOS) protein was significantly decreased, the numbers of the CD45-positive cells and those of the proliferating cell nuclear antigen-positive cells were increased in the lung tissue, and P-selectin was intensely expressed on the endothelium of the pulmonary arteries. These features were prevented by nicorandil. Late treatment with nicorandil did not palliate established pulmonary arterial hypertension nor improved survival. Thus, nicorandil inhibited development of MCT-induced pulmonary arterial hypertension but failed to reverse it. These effects were associated with marked up-regulation of diminished lung eNOS protein along with improvement of pulmonary vascular endothelial activation and anti-inflammatory and anti-proliferative effects in the lung tissue.Keywords
This publication has 38 references indexed in Scilit:
- Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.2004
- Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertensionProgress in Cardiovascular Diseases, 2002
- Bosentan Therapy for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2002
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Prostacyclin Synthase Expression Is Decreased in Lungs from Patients with Severe Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1995
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993